24/7 Market News Snapshot 28 August, 2025 – Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)

August 28, 2025

DENVER, Colo., 28 August, 2025 (www.247marketnews.com) – (NASDAQ:GLMD) are discussed in this article.
Galmed Pharmaceuticals Ltd. (GLMD) has recently shown significant momentum in the pre-market trading, with shares rising to $1.420, reflecting a 2.16% increase from the previous session’s close of $1.390. The trading volume of approximately 887.18K indicates strong investor interest, suggesting an optimistic market sentiment towards the company’s recent developments. Key resistance levels are projected at $1.450, and robust support is noted around $1.390, providing a critical framework for traders to assess market conditions and validate this bullish trend.

In conjunction with this positive trading activity, Galmed has unveiled its financial results and strategic advancements for the second quarter of 2025, highlighting its innovative approach to investment. The company has initiated the formation of a Crypto Committee, embracing a digital asset management strategy. This marks a substantial shift, with plans to allocate up to 50% of its cash reserves—approximately $10 million—into digital assets aimed at enhancing capital efficiency and boosting shareholder value. To facilitate these plans, Galmed will partner with Tectona Ltd., a firm specializing in crypto treasury management.

Moreover, Galmed has revised its collaboration with Entomus s.r.o., opting to terminate its licensing agreement for the Self-Emulsifying Drug Delivery System (SEDDS). A newly formed UK-based entity will lead the development project, with Galmed intending to acquire a 20% ownership stake through a $2 million investment, pending board approval.

As of June 30, 2025, Galmed reported cash and equivalents of approximately $20.7 million, an increase from $15.4 million at the close of 2024, alongside a net loss of roughly $2.5 million, or $0.63 per share. This financial posture underscores the company’s sustained investment in research and development while expanding its operational infrastructure, allowing it to focus on advancing its proprietary product Aramchol and diversifying its pipeline for cardiometabolic and oncological diseases. Galmed’s strategic initiatives position it for continued growth in the dynamic biopharmaceutical market.

Related news for (GLMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.